1. Brolucizumab: first approval;Markham;Drugs,2019
2. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration;Gaudreault;Invest Ophthalmol Vis Sci,2012
3. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders;Tietz;Invest Ophthalmol Vis Sci,2015
4. Brolucizumab: evolution through preclinical and clinical studies, and the implications for the management of neovascular age-related macular degeneration;Nguyen;Ophthalmology,2020
5. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration;Dugel;Ophthalmology,2020